Azitra is trading at $1.18, up 6.17% from the October 27 regular-session close of $1.11; no confirmed company-specific announcement explains the after-hours move.

  • October 26: Azitra reported positive ex vivo results for ATR-COSF; initial human-study results are anticipated by year-end, but that earlier news does not establish the reason for this move.
  • Broader indices were positive, but available evidence does not establish a direct connection to Azitra’s after-hours gain.
  • The prior session closed down 27.45%, following the split-adjusted rally the day before.